(Q36367428)

13 August 2017

1 reference

title

Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas (English)

1 reference

13 August 2017

0 references

1 reference

Barzon L

1

1 reference

13 August 2017

Zanusso M

series ordinal

2

1 reference

13 August 2017

Colombo F

series ordinal

3

1 reference

13 August 2017

Palù G

series ordinal

4

1 reference

13 August 2017

1 June 2006

1 reference

13 August 2017

1 reference

13 August 2017

13

1 reference

13 August 2017

6

1 reference

13 August 2017

539-554

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700930

13 August 2017

0 references

cites work

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Endocrine aspects of cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Gene therapy for malignant glioma: current clinical status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Local inflammation and devascularization--in vivo mechanisms of the "bystander effect" in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Imaging‐guided convection‐enhanced delivery and gene therapy of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Molecular evaluation of biopsy and autopsy specimens from patients receiving in vivo retroviral gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Transduction of glioma cells using a high-titer retroviral vector system and their subsequent migration in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Convection-enhanced delivery of macromolecules in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Gene stereotactic neurosurgery for recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Systemic activation of the immune system during ganciclovir treatment following intratumoral herpes simplex virus type 1 thymidine kinase gene transfer in an adolescent ependymoma patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

MTH-68/H oncolytic viral treatment in human high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

HSV1716 persistence in primary human glioma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Newcastle disease virus selectively kills human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Viruses in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Systemic T cell adoptive immunotherapy of malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Immunotherapy with autologous white cell infusions (“lymphocytes”) in the treatment of recurrent glioblastoma multiforme.A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Clinical studies of intrathecal autologous lymphocyte infusions in patients with malignant glioma: A toxicity study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Immunotherapy of glioblastoma with intratumoural administration of autologous lymphocytes and human lymphoblastoid interferon. A further clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Dendritic cell-based immunotherapy for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Dendritic cells as therapeutic vaccines against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

A Phase I/II Study of Herpes Simplex Virus Type 1 Thymidine Kinase “Suicide” Gene Therapy for Recurrent Glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

inferred from DOI database lookup

7 January 2021

based on heuristic

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

inferred from DOI database lookup

7 January 2021

based on heuristic

Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700930

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.CGT.7700930

1 reference

13 August 2017

1 reference